ArticleAntimicrobial agents and chemotherapy2018
Novel Pyrimidines as Antitubercular Agents.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- A green fabrication of pharmacologically relevant fused pyrimidines using recyclable caffeine-HRSC advances · 2026Article
- Pyrimidine-Based Compounds in Tuberculosis Management: A Review of their Biological and Medicinal Importance.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Review
- Evolution of Small Molecule Inhibitors ofJournal of medicinal chemistry · 2025Article
- Non-fused Pyrimidine Derivatives as Potential Pharmacological Entities: A Review.Current topics in medicinal chemistry · 2025Review
- Microwave-assisted Green Synthesis: An Approach for the Development of Anti-tubercular Agents.Current drug targets · 2025Review
- Small Molecule Benzothiophene withJournal of medicinal chemistry · 2024Article
- Microwave Induced Green Synthesis: Sustainable Technology for Efficient Development of Bioactive Pyrimidine Scaffolds.Current medicinal chemistry · 2023Review
- Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds.Molecules (Basel, Switzerland) · 2022Article
- A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-ResistantAntimicrobial agents and chemotherapy · 2022Article
- Article
- Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-ResistantACS infectious diseases · 2021Article
- Targeting Mycobacterium tuberculosis response to environmental cues for the development of effective antitubercular drugs.PLoS biology · 2021Article
- Design, Synthesis, Molecular Modeling and Antitumor Evaluation of Novel Indolyl-Pyrimidine Derivatives with EGFR Inhibitory Activity.Molecules (Basel, Switzerland) · 2021Article
- Random Forest Model Prediction of Compound Oral Exposure in the Mouse.ACS pharmacology & translational science · 2021Article
- Pruned Machine Learning Models to Predict Aqueous Solubility.ACS omega · 2020Article
- Machine Learning Platform to Discover Novel Growth Inhibitors of Neisseria gonorrhoeae.Pharmaceutical research · 2020Article
- A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.Cell chemical biology · 2020Article
- Antitubercular Triazines: Optimization and Intrabacterial Metabolism.Cell chemical biology · 2020Article
- Intrabacterial Metabolism Obscures the Successful Prediction of an InhA Inhibitor ofACS infectious diseases · 2019Article
- Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.Bioorganic & medicinal chemistry letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.